Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$2,103,150.00
Nov 1, 2020
For-profit organization
Covid 19 Vaccine: Manufacturing Feasibility Study and Engineering Design
959304
The purpose of the funding will be to support a feasibility assessment and detailed engineering design for the expansion of Therapure’s current mammalian cell culture (MCC) capacity in support of VBI’s coronavirus vaccine as well as other MCC projects and coronavirus vaccines that require insect cell/baculovirus expression systems and potentially adeno viral vectors. The two areas at Therapure’s current biomanufacturing facility that will be assessed to support pandemic vaccine manufacturing:
•Existing space within the facility
•Extension of the existing space with access to some of the existing utilities and all other systems such as Quality, Project Management, Finance and IT
$46,794.00
Oct 1, 2020
For-profit organization
Plasmid Design Optimization to Enhance Immunogenicity of Salmonella-based Vaccines for Cellular and Antibody Immune Responses
957439
The project seeks to develop novel plasmid constructs that enhance the expression and presentation of exogenous antigens upon delivery to a mammal via Salmonella vaccine vector. The vaccines will be developed for use in infectious disease and cancer indications.
$2,906,106.67
Sep 24, 2020
For-profit organization
COVID-19 Response (VI): Nasal Vaccine Development
957294
Development of a Nasal Vaccine for the prevention of coronavirus disease 2019 due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).
$1,874,945.00
Sep 21, 2020
For-profit organization
COVID 19 - Feasibility Study to Manufacture a Vaccine
956502
Enhanced conceptual engineering design for the installation of vaccine manufacturing capacity at BioVectra's current sites.
$1,000,000.00
Sep 17, 2020
215122
215122
Support pre-clinical development activities for COVID-19 vaccine
$900,000.00
Sep 17, 2020
215122
215122
Support pre-clinical development activities for COVID-19 vaccine
$500,000.00
Sep 8, 2020
For-profit organization
Covid-19: Design of a Contract Manufacturing Vaccine/Biomanufacturing Fill-Finish Facility
958184
Design of a facility, inclusive of engineering design and research in innovative formulation and fill-finish manufacturing of vaccines, therapies and other biopharmaceuticals using a Ready-To-Use (RTU) container platform for vials and prefilled syringes.
$2,500,000.00
Sep 4, 2020
Not-for-profit organization or charity
Lebanon - Response to Explosion in Beirut - UNICEF 2020
7422793 P009716001
Project activities include: (1) providing water and hygiene items to families in temporary shelters; (2) providing immediate water, sanitation and hygiene services to temporary and field hospitals, and emergency repair of plumbing systems in damaged hospitals; (3) providing health facilities with personal protective equipment (PPE) and infection prevention and control (IPC) materials, vaccine commodities and acute medicine cold chain support, health emergency kits, obstetric, newborn and midwifery kits and nutrition supplies; (4) providing child friendly spaces in affected areas and relocation sites; and (5) providing mental health and psychosocial support services to children and caregivers.
$2,821,081.00
Sep 4, 2020
For-profit organization
COVID-19 Response (VI): Oral DNA Vaccine Development
956763
The goal of this project is to develop and clinically evaluate an oral, room temperature stable DNA vaccine candidate for SARS-CoV2. The project will involve the advancement of the bacTRL-Spike COVID-19 vaccine candidate through preclinical development, process development manufacturing scale-up, and first-in-human clinical testing.
$2,655,429.00
Sep 4, 2020
For-profit organization
COVID-19 Response (VI): DPX-COVID-19 Clinical Development and DPX-CoVLP Proof-of-Concept Study
957553
In response to the global crisis, IMV has initiated the development of a vaccine to protect against the COVID-19 pandemic. We believe our targeted peptide epitope approach has the potential to optimize and exceed the safety and efficacy profile of more conventional vaccines. DPX-COVID-19 utilizes a multi-target approach, to optimize immune response against virus’ weaknesses, enhance efficacy at preventing infection and reduce potential for immune escape, even in case of a virus mutation. Fully synthetic, DPX-COVID-19 has the potential for fast and large-scale manufacturing to supply a significant number of doses rapidly compared to more conventional vaccines.